Mesoblast Limited MESO shares are trading higher on Wednesday.
The company announced that the FDA accepted its biologics license application for RYONCIL and has agreed to a priority review.
Related Link: Mesoblast Heart Failure Cell Therapy Receives Orphan Drug Status
Mesoblast is an Australian based regenerative medicine company and provides treatments for inflammatory ailments, cardiovascular disease and back pain.
Mesoblast shares traded higher by 6.39% to $4.66 at time of publication. The stock has a 52-week range between $10.88 and $3.12.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
